openPR Logo
Press release

US Generic Drug Market 2017 - Teva, Mylan, Actavis, Sandoz, Sun Pharma, Par Pharmaceuticals

10-17-2017 08:58 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: IMARC Group

US Generic Drug Market 2017 - Teva, Mylan, Actavis, Sandoz, Sun

The US generic drug market has witnessed a steady growth in the recent years. The major factors that have added to the market growth are low investment in R&D, patent expiry of innovative drugs and cost-effectiveness of generic drugs as compared to their counterparts.

Request a free sample copy of the report: http://www.imarcgroup.com/request?type=report&id=567&flag=B

The latest report by IMARC Group, titled “US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022”, finds that the US generic drug market reached a value of nearly 4 Million prescriptions in 2016, exhibiting a CAGR of 5% during 2010-2016. Over the past several years, the United States has undergone a major transformation in the pharmaceutical sector. Nearly, 80% of the total prescription drugs in the US consist of generic drugs. They are low-cost versions of the innovator drugs with same dosage, strength, risks, effects, side-effects and intended usage. Generic drugs assure that the medicines are effective and safe for the consumers. These drugs come in different forms such as oral, nebulizer, intravenous, topical and intramuscular.

Highlights of the US generic drug market:

Upcoming patent expiry of branded drugs is projected to boost the market growth.

With low manufacturing costs, these drugs are comparatively cheaper than innovative drugs.

Teva represents the leading manufacturer of generic drugs in the US.

Generic drugs can only be launched by the manufacturers once the branded drugs go off-patent. Imminent patent expiry of a huge number of blockbuster innovator drugs is expected to be one of the major factors contributing to the market growth. Moreover, generic drugs require less effort in the research & development sector, thus the cost involved in the manufacturing of these drugs are lower than the branded drugs. Owing to this, generic drugs are cheaper in comparison to their counterparts, thereby making them affordable for different income groups. This helps in reducing the healthcare expenditures of the government, patients and third-party payers. Additionally, the fact that the US pharmacists are paid incentives to prescribe cheaper generic drugs has further stimulated the market growth. Other major factors fueling the growth of the market include ageing population and prevalence of chronic diseases. According to the report, the market is anticipated to reach a value of around 5 Million prescriptions by 2022.

Read full report with TOC @ http://www.imarcgroup.com/us-generics-market

The US generic drug market is segmented into branded and unbranded generics. Presently, unbranded generic drugs are leading the market, holding for the majority of the total generic prescription volumes. On comparing the competitive landscape of the market, the key players found are Teva, Mylan, Actavis, Sandoz, Sun Pharma, Par Pharmaceuticals, Endo Pharmaceuticals, Lupin Pharmaceuticals, Dr Reddy’s and Hospira. Among these, Teva represents the leading generic manufacturer in the US, accounting for around a fifth of the total generic sales.

Browse related reports :

GCC Generic Drug Market: http://www.imarcgroup.com/gcc-generic-drug-market

US Generic Injectables Market: http://www.imarcgroup.com/us-generic-injectables-market

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.Global Cigarette Lighter Market

Contact us

IMARC Group
309 2nd St, Brooklyn, NY 11215, USA
Website: www.imarcgroup.com
Email: sales@imarcgroup.com
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Generic Drug Market 2017 - Teva, Mylan, Actavis, Sandoz, Sun Pharma, Par Pharmaceuticals here

News-ID: 775877 • Views:

More Releases from IMARC Group

GCC Pet Food Market Size is Expected to Reach USD 422.9 Million By 2033 | CAGR: 5.3%
GCC Pet Food Market Size is Expected to Reach USD 422.9 Million By 2033 | CAGR: …
GCC Pet Food Market Overview Market Size in 2024: USD 266.2 Million Market Size in 2033: USD 422.9 Million Market Growth Rate 2025-2033: 5.3% According to IMARC Group's latest research publication, "GCC Pet Food Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", the GCC pet food market size was valued at USD 266.2 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 422.9 Million by 2033, exhibiting a
GCC Residential Real Estate Market Size to Worth USD 147.77 Billion by 2033 | With a 7.50% CAGR
GCC Residential Real Estate Market Size to Worth USD 147.77 Billion by 2033 | Wi …
GCC Residential Real Estate Market Overview Market Size in 2024: USD 73.31 Billion Market Size in 2033: USD 147.77 Billion Market Growth Rate 2025-2033: 7.50% According to IMARC Group's latest research publication, "GCC Residential Real Estate Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", the GCC residential real estate market size was valued at USD 73.31 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 147.77 Billion by
GCC Drones Market Size to Surpass USD 2,005.3 Million by 2033 | With a 13.3% CAGR
GCC Drones Market Size to Surpass USD 2,005.3 Million by 2033 | With a 13.3% CAG …
GCC Drones Market Overview Market Size in 2024: USD 588.2 Million Market Size in 2033: USD 2,005.3 Million Market Growth Rate 2025-2033: 13.3% According to IMARC Group's latest research publication, "GCC Drones Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", The GCC drones market size was valued at USD 588.2 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 2,005.3 Million by 2033, exhibiting a growth rate of
Medical Imaging Market to Surpass USD 70.8 Billion by 2033, at a CAGR of 5.03%
Medical Imaging Market to Surpass USD 70.8 Billion by 2033, at a CAGR of 5.03%
Market Overview: The medical imaging market is experiencing rapid growth, driven by Growing Burden of Chronic and Age-Related Diseases, Expansion of Government-Funded Health Infrastructure and Technological Advancements in Imaging Modalities. According to IMARC Group's latest research publication, "Medical Imaging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", The global medical imaging market size reached USD 44.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach

All 5 Releases


More Releases for Generic

Prominent Generic Oncology Drugs Market Trend for 2025: Novel Formulations Trans …
Which drivers are expected to have the greatest impact on the over the generic oncology drugs market's growth? The upward trend in cancer incidence is predicted to fuel the expansion of the generic oncology drugs market. Cancer, characterized by unregulated cell proliferation affecting numerous organs, results in considerable morbidity and mortality globally. The provision of affordable generic oncology drugs is an instrumental factor in cancer care, expanding access to vital treatments,
Generic Theater Presents Flyin' West
NORFOLK, VA (August 2023) - Generic Theater inaugurates its 43rd season with Flyin' West, written by award-winning playwright and New York Times bestselling author Pearl Cleage. Terrance Afer-Anderson directs this production, running weekends September 8th - October 1st at Generic Theater, Norfolk's underground theater located in the basement of Chrysler Hall. Following the end of the Civil War, many former slaves took advantage of The Homestead Act and went West to
Generic Injectables Market growth is attributed to the increasing demand for Onc …
According to Precision Business Insights (PBI), the latest report, the generic injectables market will be worth USD 22.0 billion in 2022, growing at an 11.0% CAGR from 2022 to 2028. The global generic injectables market is segmented into the following types: Product Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Immunoglobulins, Peptide Antibiotics, Vaccines, and Others), Indication (Diabetes, Cancer, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Distribution Channel (Hospital
A Demand On Generic Drugs Market And The Need To Push The Market Of Generic Drug …
Global Generic Drugs Market A generic drug is pharmaceutical drug, which is bio-equivalent to a branded drug in all forms such as route of administration, strength, dosage, quality, intended use and performance. Generic drugs are usually approved after patent expiration of patent drugs. Generic drugs are safe, effective and FDA approved. The global market is filled with 44% of generic drugs. The global generic drugs market is driven by the rise of
Generic Drug Market: Global Generic Drug Share to Reach USD 380.60 Billion by 20 …
Zion Market Research has published a new report titled “Generic Drug Market by Brand (Pure Generic and Branded Generic) for Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory and Others Therapeutic Applications - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global generic drug market accounted for around USD 200.20 billion in 2015 and is expected to reach approximately USD 380.60 billion by
Generic Drugs: Global Collaboration Opportunities
Collaboration is the key to growth With the recent economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems. At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of